$NASDAQ:TCRR

TCRR Price Target Lowered to $1.68, Maintaining Neutral Rating for 2023.
Gallery

TCRR Price Target Lowered to $1.68, Maintaining Neutral Rating for 2023.

Trending News 🌧️ The firm maintained its Neutral rating on the stock. Wedbush's decision to lower their price target reflects [...]

By GoodWhale|March 26, 2023|Categories: Biotechnology, Market Price|Tags: $NASDAQ:TCRR, Biotechnology, NASDAQ|0 Comments

TCR2 Therapeutics Flirts With Old Highs Despite 1.60% Dip in Latest Session.
Gallery

TCR2 Therapeutics Flirts With Old Highs Despite 1.60% Dip in Latest Session.

Trending News ☀️ TCR2 ($NASDAQ:TCRR) Therapeutics Inc. had an eventful session on the stock market, closing at $1.23, which is [...]

By GoodWhale|March 2, 2023|Categories: Biotechnology|Tags: $NASDAQ:TCRR, Biotechnology, NASDAQ|0 Comments

TCR2 Therapeutics to Showcase at SVB Securities Global Biopharma Conference 2023
Gallery

TCR2 Therapeutics to Showcase at SVB Securities Global Biopharma Conference 2023

Trending News ☀️ TCR2 ($NASDAQ:TCRR) Therapeutics is set to be featured at the SVB Securities Global Biopharma Conference in 2023. [...]

By GoodWhale|February 10, 2023|Categories: Biotechnology|Tags: $NASDAQ:TCRR, Biotechnology, NASDAQ|0 Comments

TCR2 THERAPEUTICS Volatility Jumps to 7.85%: Prepare for the Unexpected
Gallery

TCR2 THERAPEUTICS Volatility Jumps to 7.85%: Prepare for the Unexpected

Trending News 🌥️ TCR2 THERAPEUTICS ($NASDAQ:TCRR) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel [...]

By GoodWhale|December 28, 2022|Categories: Biotechnology|Tags: $NASDAQ:TCRR, Biotechnology, NASDAQ|0 Comments

TCR2 Therapeutics Submits Matters to a Vote of Security Holders

Trending News ☀️ TCR2 ($NASDAQ:TCRR) Therapeutics Inc. is a clinical-stage immuno-oncology company developing novel T cell therapies for the treatment [...]

By GoodWhale|November 23, 2022|Categories: Biotechnology|Tags: $NASDAQ:TCRR, Biotechnology, NASDAQ|0 Comments

TCR2 Therapeutics Plans to Raise $80 Million in IPO

Trending News 🌥️ TCR2 ($NASDAQ:TCRR) Therapeutics is a clinical-stage immuno-oncology company that is developing T-cell therapies for the treatment of [...]